Recently, the team of Yang Xiaoming, a researcher at Sinopharm China Biologics, recently found that a monoclonal antibody that is effective against the Delta variant strain neutralizes the activity IC50 up to 5ng/ml.
Important discovery! Monoclonal antibodies are effective against COVID-19 variants such as Delta
At the same time, the research team also used ifNAR-/mouse model transduced by hACE2-adenovirus (hACE2-ADV) to evaluate the prevention and treatment effect of 2B11 on SARS-CoV-2 infection. The results showed that compared with the control group, the administration of 2B11 before or after attacking the virus could significantly reduce the weight loss caused by viral infection and the viral load of the lungs, and further analysis of lung pathological tissue slices showed that the administration of 2B11 could significantly reduce the lung inflammation caused by viral infection.
Crystalline structure of 2B11-Fab and SARS-CoV-2RBD complexes
The Delta strain (B.1.617.2) has become the main strain of covid-19 transmission worldwide, and it is also a variant that is currently circulating in China. Recent supplementary research results show that 2B11 has a highly consistent neutralizing activity with wild strains, indicating that 2B11 has great application value in the short-term prevention and early treatment of new coronary pneumonia caused by Delta strains.
At present, the clinical declaration of the 2B11 antibody is being promoted in an orderly manner, with a view to using it for the prevention and control of the relevant new crown epidemic in China as soon as possible.
The results were published online in Cell Discovery (a sub-journal of Nature) under the title "Screeningof potent neutralizing antibodies against SARS-CoV-2 using convalescentpatients-derived phage-display libraries" The study promises to be a useful weapon against the mutant strain.
The project partners are the Shanghai Advanced Research Institute of the Chinese Academy of Sciences and the Wuhan Institute of Virology of the Chinese Academy of Sciences. The corresponding author of the paper is Yang Xiaoming, a researcher of China Biology, and the first author is Dr. Pan Yongbing, Antibody Research Department of Wuhan Institute of Biological Products.
What is a monoclonal antibody?
As a targeted therapeutic drug, monoclonal antibodies have the characteristics of strong specificity, significant efficacy and low toxicity, and are known as "biological missiles", showing excellent efficacy and broad application prospects in the treatment of a variety of diseases. In response to viral infectious diseases, monoclonal antibodies with neutralizing effects can specifically neutralize the virus and prevent the virus from entering the cell proliferation, which can be used as a short-term prevention of high-risk groups and for the treatment of post-viral diseases, so it is also a hot spot in the global new crown epidemic prevention and control research.
Source: @State-owned Xiaoxin @China BioCNBG